All Blogs
Sep 05, 2024
Pensar Medical’s Partnership with Centurion Therapeutics; BD’ Acquisition of Critical Care; Haleon’s Launch of Eroxon; embecta Receives FDA Clearance; INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor; Median Technologies’ Pivotal REALITY Study
Pensar Medical Entered Into a Partnership with Centurion Therapeutics for Innovative Negative Pressure Wound Therapy System On Aug 29, 2024, Pensar Medical, a pioneer in negative pressure wound therapy (NPWT), announced a strategic partnership with Centurion Therapeutics to distribute the Microdoc® sNPWT (...
Read More...
Sep 04, 2024
The Protein Chip: Revolutionizing Protein Analysis and Discovery
In the rapidly evolving field of biotechnology, the quest to understand the complexity of proteins and their functions has led to the development of innovative tools and technologies. One such breakthrough is the protein chip, a powerful tool that has transformed the landscape of protein analysis. What Are Prote...
Read More...
Sep 03, 2024
Bayer Phase III NSCLC Trial; D&D Pharmatech Gets FDA Nod for GLP-1R Agonist in Multiple Scletosis; Merck Halts Two KEYTRUDA Trials; Novartis Expands LEQVIO After Phase III Success; Alnylam Reports Strong Phase III Data for Vutrisiran
Bayer Starts Phase III Trial In Non-Small Cell Lung Cancer (NSCLC) Bayer has officially enrolled the first patient in the global Phase III SOHO-02 trial, which will evaluate the efficacy and safety of BAY 2927088 as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutat...
Read More...
Sep 02, 2024
CAR T-Cell Therapies in Non-Hodgkin’s Lymphoma Treatment: A Revolutionary Approach
CAR-T cells offer a lasting benefit through a single treatment, sparing patients with high-risk conditions from the toxicity associated with salvage chemotherapy and autologous transplants. These approvals have changed the standard of care for patients who are either resistant to initial treatment or experience ear...
Read More...
Aug 30, 2024
NMIBC Treatment Paradigm Evolution: A Look At The Clinical Development Shift From High-Risk Bcg Unresponsive To Untapped High-Risk Bcg Naïve And Intermediate-Risk NMIBC
A high cure rate characterizes Non-muscle Invasive Bladder Cancer (NMIBC), yet there is a notable risk of recurrence and progression to muscle-invasive disease. Effective NMIBC management involves precise local resection, staging, and a risk-based approach with intravesical agents. The conventional gold standard fo...
Read More...
Aug 29, 2024
Insulet Corporation’s Omnipod® 5 Automated Insulin Delivery System Receives FDA Approval; FDA Gives Green Light to Expand Vericel’s MACI Arthro Label; SkinCure Oncology Announces New Study of Non-melanoma Skin Cancer Through Image-guided Superficial Radiation Therapy; SDC’s BYOD ePRO Solution Clinical Trial; PaceMate® Acquires Paceart Optima™ System; KARL STORZ Acquires a US-headquartered Company
FDA Cleared the Omnipod® 5 Automated Insulin Delivery System for Use in People with Type 2 Diabetes On August 26, 2024, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that its groundbreaking Omnipod 5 Automated Insulin Delivery Syst...
Read More...
Aug 28, 2024
Top 7 Emerging Vaccinia Virus-associated Oncolytic Virus Therapies
Vaccinia virus-associated oncolytic virus therapies represent a promising approach to cancer treatment, leveraging the ability of the vaccinia virus to selectively infect and destroy cancer cells. The vaccinia virus, historically used in the smallpox vaccine, has been engineered to serve as an oncolytic virus due t...
Read More...
Aug 27, 2024
Merck’s WINREVAIR™ EU Approval; BALVERSA for Urothelial Carcinoma; Novartis and Versant’s Borealis Launched; Moderna’s RSV mRESVIA® EU Approval; FDA Nods RYBREVANT® and LAZCLUZE™ for EGFR-mutated Lung Cancer
Merck’s WINREVAIR Approved by the European Commission for PAH in Adults with Functional Class II-III Merck has secured European Commission (EC) approval for WINREVAIR™ (sotatercept), marking it as the first activin signaling inhibitor therapy for pulmonary arterial hypertension (PAH) approved across all 27 EU me...
Read More...
Aug 26, 2024
Imbalance Between BCG Supply and Increased Demand: The Crisis Impacting Bladder Cancer Treatment
The BCG vaccine, a significant medical breakthrough developed in the early 20th century, is derived from a strain of Mycobacterium bovis initially created by the University of Illinois as a vaccine against tuberculosis. For NMIBC, BCG is administered intravesically to reduce the risk of cancer recurrence and progre...
Read More...
Aug 23, 2024
Exploring Growth Opportunities in the Hypophosphatasia Treatment Market: Navigating the Ultra-rare Disease Landscape
Quick Facts According to DelveInsight’s analysis, in 2023, the total diagnosed prevalent cases of hypophosphatasia, an ultra-rare disease, was approximately 6,200 in the 7MM. While almost 85% have less severe forms of the disease, severity may vary based on genetic and environmental factors. Due to the low n...
Read More...